Nation’s Kidney Community Calls for Urgent Policy Action During National Kidney Month to Improve Kidney Care
WASHINGTON – Kidney Care Partners (KCP) – the nation’s largest non-profit, non-partisan kidney care coalition dedicated to protecting access to care and comprised of more than 30 organizations, including patients, dialysis professionals, physicians, nurses, researchers, therapeutic innovators, transplant coordinators, and manufacturers – in recognition of National Kidney Month is highlighting its 2025 policy priorities to address…
Dr. Mahesh Krishnan Of Kidney Care Partners On 5 Things We Must Do To Improve the US Healthcare System
We must figure out how to create settings that are most beneficial to the patient. Often, the site of care that is most convenient for the patient isn’t able to provide needed services. For example, within dialysis, there are services that could be done in the dialysis clinic but aren’t because it’s unclear what providers…
Kidney Care Partners Congratulates Robert F. Kennedy Jr. Confirmation as U.S. Secretary of Health and Human Services
WASHINGTON, DC – Kidney Care Partners (KCP) – The nation’s largest kidney coalition, comprised of physician groups, providers, patient advocacy groups, manufacturers and researchers congratulates Robert F. Kennedy Jr. on his approval by the U.S. Senate to serve as the next Secretary of the United States Department of Health and Human Services (HHS). The kidney care community…
Kidney Care Partners Submits Comments on CMS CY26 Medicare Advantage and Part D Advance Notice
WASHINGTON – Kidney Care Partners (KCP) – the nation’s leading kidney care multi-stakeholder coalition representing patient advocates, physician organizations, health professional groups, dialysis providers, researchers, and manufacturers – recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to its calendar year (CY) 2026 policy and payment proposals for Medicare Advantage…
Phosphate binder rule is disease-specific discrimination
In April, CMS issued guidance for the inclusion of oral-only drugs in the end-stage renal disease bundled payment. The directive included Xphozah as a renal dialysis service. Xphozah, (tenapanor, Ardelyx) is a first-in-class phosphate absorption inhibitor approved to lower serum phosphorus levels for adults on dialysis. CMS intends to include the agent in the ESRD prospective…
Restore Protections for Dialysis Patients Act Reaches 50 Cosponsors, Kidney Care Partners Calls for Additional Congressional Action
WASHINGTON – Kidney Care Partners (KCP) – the nation’s largest non-profit, non-partisan kidney care coalition dedicated to protecting access to care and comprised of more than 30 organizations, including patients, dialysis professionals, physicians, nurses, researchers, therapeutic innovators, transplant coordinators, and manufacturers – today thanks the 50 members of the U.S. House of Representatives who have signed…
CMS increases payment for dialysis facilities, includes oral-only drugs in the bundle
CMS issued a final rule increasing the End-stage Renal Disease Prospective Payment System base rate to dialysis facilities by about 2.7% to $273.82 beginning Jan. 1, 2025, according to an agency press release. The final rate is higher than the 2.2% increase to $273.20 in the proposed rule circulated in July and up from the 2024 base…
Discount criticism of N.J. library protection bill | Letters
As a healthcare professional, it’s my duty to ensure that dialysis treatment – a life-sustaining procedure over 20,000 New Jerseyans living with kidney failure depend on – is as accessible and seamless as possible. For over 40 years, that job was made easier by a law that provided patients on dialysis with the option to…
ESRD Pay Rule Cements Oral-Only Drugs In Bundled Payment Despite Stakeholder Opposition
CMS on Friday (Nov. 1) finalized a plan to add oral-only drugs to its End-Stage Renal Disease bundled payment system despite stakeholders’ efforts to delay the policy, including legislation passed by the House Energy & Commerce Committee that would have excluded the drugs from the ESRD bundling for another two years. Click here to see the full…
Kidney Care Partners Supports Policies to Expand Home Dialysis and Improve Reimbursement for Phosphate-Lowering Drugs, Remains Concerned CMS Has Not Addressed Barriers to Patient Access to Innovative Treatments
WASHINGTON – Kidney Care Partners (KCP) – the nation’s leading kidney care multi-stakeholder coalition representing patient advocates, physician organizations, health professional groups, dialysis providers, researchers, and manufacturers – issued the following comments in response to the recently released final Calendar Year 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services…